IDEAS home Printed from https://ideas.repec.org/p/udc/wpaper/wp462.html
   My bibliography  Save this paper

Análisis Comparativo de Precios de Medicamentos en América Latina

Author

Listed:
  • Roberto Álvarez
  • Aldo González

Abstract

Este trabajo realiza una comparación de precios de medicamentos entre las seis principales economías de América Latina. Se emplea un modelo econométrico de panel con efecto fijo por país que controla por un variado conjunto de características de los fármacos, abarcando un total de 19.741 unidades que fueron comercializadas en el período 2010 - 2015. La comparación se efectúa tanto a nivel mayorista como en venta final a público y también por tipo de medicamento –innovador, similar y genérico. A nivel agregado y en salida de farmacia, el ranking de país más barato a más caro es el siguiente: 1° Perú, 2° México, 3° Argentina, 4° Chile, 5° Colombia y 6° Brasil. En innovadores, Argentina y luego Perú serían los países con menores precios a público final. En productos similares o genéricos de marca los precios más bajos a público se encuentran en México y Argentina, mientras que para genéricos puros, Perú y luego Chile serían los más baratos. El orden de los países en el ranking no cambia sustantivamente si la comparación se realiza con precios a salida de laboratorio.

Suggested Citation

  • Roberto Álvarez & Aldo González, 2018. "Análisis Comparativo de Precios de Medicamentos en América Latina," Working Papers wp462, University of Chile, Department of Economics.
    • Handle: RePEc:udc:wpaper:wp462
    as

    Download full text from publisher

    File URL: http://www.econ.uchile.cl/uploads/publicacion/5f3c7f0dcd767d1d119f9df8ef1e7424bdbbcba5.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Productivity Commission, 2001. "International pharmaceutical price differences," Others 0107004, University Library of Munich, Germany.
    2. Patricia M. Danzon & Michael F. Furukawa, 2011. "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers 17226, National Bureau of Economic Research, Inc.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Eduardo Pontual Ribeiro & Victor Gomes, 2016. "Retail Entry Effects On Pharmaceuticals Prices: A View From Large Retail Chains In Brazil," Anais do XLIII Encontro Nacional de Economia [Proceedings of the 43rd Brazilian Economics Meeting] 139, ANPEC - Associação Nacional dos Centros de Pós-Graduação em Economia [Brazilian Association of Graduate Programs in Economics].
    2. Gianluca Baio & Laura Magazzini & Antonio Nicita & Fabio Pammolli & Massimo Riccaboni, 2003. "Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato," Working Papers CERM 0-2003, Competitività, Regole, Mercati (CERM).
    3. Bence Kovács & Miklós Darida & Judit Simon, 2021. "Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients," IJERPH, MDPI, vol. 18(18), pages 1-20, September.
    4. Salas-Vega, Sebastian & Shearer, Emily & Mossialos, Elias, 2020. "Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US," Social Science & Medicine, Elsevier, vol. 258(C).
    5. Morgan, Steve & McMahon, Meghan & Greyson, Devon, 2008. "Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia," Health Policy, Elsevier, vol. 87(2), pages 133-145, August.
    6. Ming Liu & Sumner la Croix, 2013. "A Cross-Country Index of Intellectual Property Rights in Pharmaceutical Innovations," Working Papers 201313, University of Hawaii at Manoa, Department of Economics.
    7. John Quiggin, 2005. "Pharmaceuticals and Intellectual Property: The US-Australia FTA," Agenda - A Journal of Policy Analysis and Reform, Australian National University, College of Business and Economics, School of Economics, vol. 12(2), pages 145-158.
    8. George A. Chressanthis & Nayla G. Dahan & Kevin J. Fandl, 2015. "The Effects of State Pharmacy Drug Product Selection Laws on Statin Patient Generic-To-Branded Drug Switch-Backs," The American Economist, Sage Publications, vol. 60(1), pages 26-51, May.
    9. Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
    10. Berndt, Ernst R & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," CEPR Discussion Papers 9140, C.E.P.R. Discussion Papers.
    11. Sotiris Vandoros, 2014. "Therapeutic Substitution Post‐Patent Expiry: The Cases Of Ace Inhibitors And Proton Pump Inhibitors," Health Economics, John Wiley & Sons, Ltd., vol. 23(5), pages 621-630, May.
    12. Hokkanen, Joni & Kangasharju, Aki & Linnosmaa, Ismo & Valtonen, Hannu, 2012. "Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland," Working Papers 35, VATT Institute for Economic Research.
    13. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
    14. Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.
    15. Alvarez E., Roberto & González, Aldo, 2020. "A comparative analysis of medicine prices in Latin America," Revista CEPAL, Naciones Unidas Comisión Económica para América Latina y el Caribe (CEPAL), April.
    16. Frank R. Lichtenberg, 2019. "How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013," NBER Working Papers 25483, National Bureau of Economic Research, Inc.
    17. John Quiggin, 2005. "How to kill a country?: The USÐAustralia Free Trade Agreement, pharmaceuticals and intellectual property," Australian Public Policy Program Working Papers WP1P05, Risk and Sustainable Management Group, University of Queensland.
    18. Jaume Puig-Junoy, 2012. "Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?," Applied Health Economics and Health Policy, Springer, vol. 10(6), pages 441-451, November.
    19. Doran, Evan & Robertson, Jane & Henry, David, 2005. "Moral hazard and prescription medicine use in Australia--the patient perspective," Social Science & Medicine, Elsevier, vol. 60(7), pages 1437-1443, April.
    20. Farasat A.S. Bokhari & Weijie Yan, 2020. "Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2020-04, Centre for Competition Policy, University of East Anglia, Norwich, UK..

    More about this item

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:udc:wpaper:wp462. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Mohit Karnani (email available below). General contact details of provider: https://edirc.repec.org/data/deuclcl.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.